financetom
Business
financetom
/
Business
/
Update: Secure Energy Services Loses 1% as Q3 Net Income Slumps and 2025 Adjusted EBITDA Guidance Reduced
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Secure Energy Services Loses 1% as Q3 Net Income Slumps and 2025 Adjusted EBITDA Guidance Reduced
Oct 30, 2025 9:29 AM

11:52 AM EDT, 10/30/2025 (MT Newswires) -- (Updates shares.)

Secure Energy Services (SES.TO) reported Thursday a lower net income in the third quarter on one-time charges, while the company reduced its 2025 adjusted EBITDA guidance due to weak market conditions.

The company's net income slumped to C$1 million from $94 million as it took a one-time non-cash provision of $55 million related to an underutilized crude storage contract in the third quarter.

Secure also recorded a one-time current and deferred tax recovery of $30 million. Excluding the non-recurring items, the company said its net income was relatively consistent year over year.

Adjusted EBITDA rose 17% year over year to $135 million due to investments in the metals recycling business, higher pricing across key service lines, and cost optimizations across our network, Secure said.

The company cut its 2025 adjusted EBITDA guidance to $500 million from the previous target of $510 million-$540 million, reflecting weakness in the metals recycling business and reduced industry drilling and completion activity due to low benchmark oil prices.

"Our core waste and infrastructure network continues to perform in line with expectations, and underscores the strength and stability of SECURE's recurring cash flow even amid lower oil prices and disciplined producer spending," president and chief executive officer Allen Gransch said.

Secure's shares were last seen down $0.26 to $18.04 on the Toronto Stock Exchange.

Price: 18.06, Change: -0.24, Percent Change: -1.31

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved